Home
Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) For Wet AMD, UK (Medical News Today) Print E-mail
Friday, 29 August 2008
Novartis Pharmaceuticals UK Ltd (Novartis) welcomed the Final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance for age-related macular degeneration. NICE guidance recommends Lucentis(R) (ranibizumab) for the treatment of patients with wet age-related macular degeneration (wet AMD).
Read more
Related news items:

 
< Prev   Next >